"Breakthrough product" designation would speed drugs to patients

04/24/2012 | Brookings Institution (Washington, D.C.)

Recently proposed Senate legislation to designate certain experimental drugs as "breakthrough products" would allow the FDA to streamline the approval process without compromising safety, write Mark B. McClellan, director of the Brookings Institution's Engelberg Center for Health Care Reform, and Ellen Sigal with Friends of Cancer Research. The designation would reduce the total time and cost to develop the most promising treatments and minimize the number of patients receiving placebo or a treatment known not to work well, they write.

View Full Article in:

Brookings Institution (Washington, D.C.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA